• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ANIP

ANIP

ANI Pharmaceuticals, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD75.23

+0.58 (+0.78%)

Rating:B

Company Profile

CEO

Nikhil Lalwani

IPO Date

2000-05-05

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$74.24

Prev. Close

$74.65

Day Low

$73.54

Day High

$75.85

52W Low

$59.61

52W High

$99.50

Market Cap

$1.71B

Volume

0.25M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

38.7%

Avg Negative

3.4%

Avg Neutral

57.9%

News Feed

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome

Business Wire·8/31/2021·↑ positive

ANI Pharmaceuticals' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/6/2021·↓ negative

ANI Pharmaceuticals Reports Second Quarter 2021 Results

Business Wire·8/6/2021·↑ positive

Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research·7/30/2021·↑ positive

ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA

Business Wire·7/6/2021·↑ positive

A Low Valuation, High Growth Target: ANI Pharmaceuticals

Seeking Alpha·6/30/2021·↑ positive

ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021

Business Wire·6/15/2021·↑ positive

Post Earnings Assessment On ANI Pharmaceuticals

Seeking Alpha·5/11/2021·↑ positive

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/7/2021·↓ negative

ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Top Estimates

Zacks Investment Research·5/7/2021·↑ positive